逸超医疗 is an innovative medical imaging equipment manufacturer focused on researching and producing the new "E超" device as a global third‑generation ultrasound platform. The company positions E超 as the successor to B‑mode and color ultrasound and says its system platform runs at speeds hundreds of times faster than traditional color ultrasound, earning the moniker "5G" ultrasound. The technology is described as offering quantitative, objective, and visual technical advantages that deliver clinical value. Those attributes have reportedly led to rapid recognition and adoption among many physicians. Financially, the company recently completed a Series B financing round exceeding RMB 100 million. The article does not detail further commercialization milestones, operating metrics, or additional use of proceeds beyond continued development and production.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2024